NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
Estimated value
—
Awarded value
£832.8m
Suppliers
33
Lots
2
Published
09 Jun 2026
Description
NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.
Scope
- Reference
- C414011
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2026 to 31 Aug 2028Possible extension to 31 Aug 2030
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
- CPV classifications
- 33600000
- Contract locations
- North West England, United KingdomSouth East England, United KingdomSouth West England, United KingdomLondon, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomNorth East England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated only in the procurement documents | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 2 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£813.9m
Award date
31 May 2026
Contract start
31 Aug 2026
Contract end
31 Aug 2028
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 - Tranche B for London & South of England | £541.5m | complete |
| 2 | Lot 2 - Ustekinumab for North of England and Midlands & East | £50.9m | complete |
Award 1· 25 suppliers
Awarded 31 May 2026 · Contract period 31 Aug 2026 — 31 Aug 2028
Award 2· 8 suppliers
Awarded 31 May 2026 · Contract period 31 Aug 2026 — 31 Aug 2027
Total lots
2
Awarded
2
Estimated total
£592.4m
Awarded total
£832.8m
Lot 1 - Tranche B for London & South of England
Start
31 Aug 2026
End
31 Aug 2028
Estimated
£541.5m
CPV
Lot 2 - Ustekinumab for North of England and Midlands & East
Start
31 Aug 2026
End
31 Aug 2027
Estimated
£50.9m
CPV
Other contracts from NHS England
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to AMGEN LIMITED· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| Ustekinumab | contract | — | 15 Jun 2026 |
| Transitional Drugs 7 | contract | — | 05 Jun 2026 |
| Transitional Drugs 6 | contract | — | 30 Mar 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NP49425 Generic and Biosimilar Transition Medicines | contract | — | 19 Dec 2025 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 | contract | — | 04 Dec 2025 |
| Project/Contract NHS National Framework for Denosumab Injection | contract | — | 02 Oct 2025 |
| Romiplostim (Nplate®) | contract | — | 10 Sept 2025 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | contract | £47.0m | 29 Jul 2025 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | contract | — | 29 Jul 2025 |